TickerGuard
Buy Day today: Neutral (47) Mixed market breadth · no major macro event
PACB

Pacific Biosciences of California

Healthcare · Medical Devices

2.70$ +0.7% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow PACB
Line item 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-773.6% -4,251.2% -55,435.6% -7,287.7% -304.1% -295.7% -105.9% -84.9% -51.6% -74.9% -72.2% -84.5% -86.2% 24.7% -85.2% -205.1% -132.9% -133.8% -69.5%
72.9% 331.5% 3,040.0% 308.2% 17.1% 25.6% 20.0% 7.0% 4.0% 4.3% 9.0% 9.2% 10.9% 11.8% 8.9% 13.5% 16.3% 34.6% 241.5%
76.7% 236.1% 2,688.9% 578.9% 36.6% 37.4% 35.1% 16.4% 14.9% 21.6% 21.8% 29.4% 18.0% 22.2% 61.9% 61.3% 36.0% 46.1% 26.0%
– – – – 37.2% 38.5% 33.7% 17.2% 14.7% 21.4% 22.5% 29.2% -1.6% -20.9% 28.3% 67.8% – – –
75.2% 35.8% 3,657.0% 170.9% -35.4% 3.9% 119.7% -1.3% -33.8% -19.8% -6.4% 7.2% -3.3% -3.5% 16.1% -42.1% -29.4% -26.3% 2.8%
140.9% 633.0% 3,834.8% 314.2% 27.4% 6.6% 3.2% 2.7% 3.2% 9.0% 11.2% 2.4% 3.1% 1.3% 4.5% 13.2% 4.4% 4.0% 1.7%
-847.8% -1,153.5% 13,773.3% -8,258.7% 19.0% 237.8% -117.5% 32.3% 9.3% -16.4% -1.7% -48.9% 68.3% -278.0% -519.9% 90.5% 2.3% 80.5% 72.2%
– – – – 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% – – – – – – – –
-0.2% – -5.9% – 22.9% 10.4% 81.6% 69.3% 39.3% 72.7% 78.4% 136.3% 9.4% 296.4% 250.3% – – – –
– – – – – – 70.1% -7.4% -4.9% -5.0% -4.8% -20.3% -17.6% -20.3% 685.9% -1.3% -0.9% -0.3% 0.0%
-10.4% 13,310.4% 49,640.0% 19,036.1% 22.9% 10.4% 151.8% 69.3% 39.3% 72.7% 73.6% 136.3% 29.2% 319.2% 896.1% 7.5% 58.0% -27.9% 2.1%
-1,631.8% 7,905.8% 7,977.8% 3,489.7% -262.2% -47.4% -71.6% 16.6% -3.0% -18.6% -0.3% 3.0% 11.3% 65.9% 291.1% -107.2% -72.4% -80.6% 4.8%
-914.5% -4,884.1% -59,270.4% -7,601.9% -331.5% -302.2% -109.1% -87.6% -54.9% -83.9% -83.4% -86.8% -89.3% 23.4% -89.7% -218.3% -137.3% -137.8% -71.2%

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?